LET_LSE_PMS_0019/09/26

All correspondence should be addressed to the Director General

In reply, please quote .....

ZAMBIA MEDICINES REGULATORY AUTHORITY

PUBLIC NOTICE

Date: 14th September 2026

To: Distributors, Wholesalers, Retail Pharmacies, Public and Private Hospitals & Clinics, Healthcare Professionals, Consumers

URGENT MEDICAL PRODUCT ALERT: ZAMRA CLARIFIES ON NIFEDIPINE RECALL NOTICE CIRCULATING ON SOCIAL MEDIA

FOR IMMEDIATE RELEASE: The Zambia Medicines Regulatory Authority (ZAMRA) has noted a message circulating on social media claiming that members of the public have been advised to immediately stop taking Nifedipine and return the medicine to pharmacies.

The Authority wishes to clarify that neither ZAMRA nor the Zambia National Broadcasting Corporation (ZNBC) issued or aired such a recall notice.

However, the Authority wishes to inform the public that the Medicines Control Authority of Zimbabwe (MCAZ) has issued a recall notice concerning a specific Nifedipine product and specified batches.

MCAZ Circular No. 22 of 2026 relates to Nifelat (Nifedipine 10mg Tablets), batches 112033 and 117367, following out-of-specification results identified during stability testing by the manufacturer, Remedica Ltd.

Product details:

s/n	Name of Product	Affected Batch Number(s)	Nature of OOS
1.	Nifelat (Nifedipine 10mg Tablets	112033 & 117367	Dissolution-profile OOS, predominantly affecting the early stages of dissolution. The remaining dissolution stages were within specification.

Importantly, MCAZ has clarified that the recall does NOT apply to all Nifedipine products, and guided that other brands, strengths and batch numbers of Nifedipine are not affected by the recall.

Head Office
Plot No: 2350/M
Off Kenneth Kaunda International Airport Road.
P.O. Box 31890, Lusaka, ZAMBIA
Tel: +260 211 432 350 /432 351
E-mail: pharmacy@zamra.co.zm

Report Adverse Reactions to:
Pharmacovigilance Unit, Lusaka
Tel: +260 211 432 356
E-mail: npvu@zamra.co.zm
Website: www.zamra.co.zm

The Zambian public is therefore urged not to panic or stop taking prescribed Nifedipine solely on the basis of the circulating social media message. Patients should continue taking their medicines as prescribed and seek guidance from a healthcare professional if they have concerns about a particular product or batch.

We will continue to monitor the situation and provide any further guidance that may be necessary, and members of the public are hereby encouraged to avoid sharing unverified health messages and to rely on ZAMRA and other official regulatory authorities for factual information.

REQUIRED ACTION

All pharmaceutical outlets and members of the public who may be in possession of these products should place them in quarantine and return them to their supplier(s) or place of purchase. Alternatively, contact the National Pharmacovigilance Unit at the Zambia Medicines Regulatory Authority by phone: +260 211 432 356/+260 //956 521 094 or email at: npvu@zamra.co.zm or pharmacy@zamra.co.zm.

Should you need further clarification, please do not hesitate to contact our Secretariat.

Makomani Siyanga (Mr)
DIRECTOR-GENERAL

Annexure 1: MCAZ Recall and Advisory Notice